搜索
 > 【CD40 Ligand】重组蛋白信息

CD40 Ligand信息

英文名称:CD40 ligand
中文名称:CD40配体
靶点别称:CD40 ligand,T-cell antigen Gp39,CD40-L,TNFSF5,CD40LG,CD40L ,TRAP,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,TNF-related activation protein,CD_antigen=CD154
上市药物数量:0
临床药物数量:12
最高研发阶段:临床二期

CD40 Ligand 分子别名

CD40LG,CD154,CD40L,HIGM1,IGM,IMD3,T-BAM,TNFSF5,TRAP,gp39

CD40 Ligand 分子背景

CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members. CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

CD40 Ligand 参考文献

CD40 Ligand临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CD154 gene therapy (Tragen) ISF-154 临床二期 圣迭戈加利福尼亚大学, Tragen Pharmaceuticals 慢性淋巴细胞白血病
MEDI-4920 MEDI-4920; VIB-4920,MEDI4920; VIB4920 临床一期 MedImmune, Viela Bio 干燥综合征, 类风湿性关节炎 详情
Toralizumab IDEC-131; E-6040 临床二期 Seikagaku, 百健, 卫材 自身免疫疾病, 银屑病, 系统性红斑狼疮, 多发性硬化症, 类风湿性关节炎, 特发性血小板减少性紫癜, 克罗恩氏病
Anti-CD40L antibody (Bristol-Myers Squibb) 临床二期 百时美施贵宝 免疫缺陷性疾病
LOAd-703 LOAd-703,LOAd 703,LOAd703 临床二期 Uppsala University, Lokon Pharma 结肠直肠癌, 卵巢癌, 胰腺癌, 胆道癌 详情
Ruplizumab BG-9588 临床二期 百健 血友病A, 自身免疫疾病, 系统性红斑狼疮, 免疫性血小板减少性紫癜, 多发性硬化症, 肾移植排斥反应 详情
ABBV-428 ABBV-428 临床一期 艾伯维 实体瘤 详情
BIIB-063 BIIB-063 临床一期 百健 干燥综合征 详情
Dapirolizumab pegol CDP-7657; Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CD40L - Fab,CDP7657 临床二期 百健, 优时比 系统性红斑狼疮 详情
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA,rVV 740CTA 临床一期 University Hospital Basel 乳腺癌 详情
Letolizumab BMS-986004; BMS2h-572-633-CT-L2 ,BMS986004,BMS2h-572-633-CT-L2 临床二期 百时美施贵宝 免疫性血小板减少性紫癜 详情
AdCD40L 临床二期 Uppsala University 膀胱癌, 黑色素瘤

消息提示

请输入您的联系方式,再点击提交!

确定